Jonas Ghouse1,2, Gustav Ahlberg1,2, Henning Bundgaard3, Morten S Olesen1,2. 1. 1Laboratory for Molecular Cardiology, Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. 2. 2Laboratory for Molecular Cardiology, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark. 3. 3Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Abstract
OBJECTIVE: To evaluate the association between PCSK9 predicted loss-of-function (pLoF) variants and glycemic traits, hepatobiliary function, and neurocognitive traits. RESEARCH DESIGN AND METHODS: We identified carriers of PCSK9 pLoF variants in UK Biobank exome sequencing data. We assessed the aggregate effects of these variants on lipid and lipoprotein traits, which served as a positive control. Association of PCSK9 pLoF carrier status and glycemic traits, hepatobiliary function, and neurocognitive traits was then evaluated as a measure for adverse effects. RESULTS: We identified 374 individuals carrying one of 41 unique PCSK9 pLoF variants. As expected, we found that PCSK9 pLoF carriers had significantly lower LDL cholesterol C levels (P = 7.4 × 10-55) and apolipoprotein B levels (P = 7.6 × 10-50) than did noncarriers. However, we found no significant associations between pLoF carrier status and glycemic traits, hepatobiliary function, and neurocognitive traits (P > 0.05). CONCLUSIONS: Our results do not support adverse effects of PCSK9 pLoF variants on glycemic traits, hepatobiliary function, or neurocognitive traits.
OBJECTIVE: To evaluate the association between PCSK9 predicted loss-of-function (pLoF) variants and glycemic traits, hepatobiliary function, and neurocognitive traits. RESEARCH DESIGN AND METHODS: We identified carriers of PCSK9 pLoF variants in UK Biobank exome sequencing data. We assessed the aggregate effects of these variants on lipid and lipoprotein traits, which served as a positive control. Association of PCSK9 pLoF carrier status and glycemic traits, hepatobiliary function, and neurocognitive traits was then evaluated as a measure for adverse effects. RESULTS: We identified 374 individuals carrying one of 41 unique PCSK9 pLoF variants. As expected, we found that PCSK9 pLoF carriers had significantly lower LDL cholesterol C levels (P = 7.4 × 10-55) and apolipoprotein B levels (P = 7.6 × 10-50) than did noncarriers. However, we found no significant associations between pLoF carrier status and glycemic traits, hepatobiliary function, and neurocognitive traits (P > 0.05). CONCLUSIONS: Our results do not support adverse effects of PCSK9 pLoF variants on glycemic traits, hepatobiliary function, or neurocognitive traits.
Authors: Matthew T Mefford; Robert S Rosenson; Mary Cushman; Michael E Farkouh; Leslie A McClure; Virginia G Wadley; Marguerite R Irvin; Vera Bittner; Monika M Safford; Ransi Somaratne; Keri L Monda; Paul Muntner; Emily B Levitan Journal: Circulation Date: 2017-11-16 Impact factor: 29.690
Authors: Robert P Giugliano; François Mach; Kenton Zavitz; Christopher Kurtz; Kyungah Im; Estella Kanevsky; Jingjing Schneider; Huei Wang; Anthony Keech; Terje R Pedersen; Marc S Sabatine; Peter S Sever; Jennifer G Robinson; Narimon Honarpour; Scott M Wasserman; Brian R Ott Journal: N Engl J Med Date: 2017-08-17 Impact factor: 91.245
Authors: Marc S Sabatine; Lawrence A Leiter; Stephen D Wiviott; Robert P Giugliano; Prakash Deedwania; Gaetano M De Ferrari; Sabina A Murphy; Julia F Kuder; Ioanna Gouni-Berthold; Basil S Lewis; Yehuda Handelsman; Armando Lira Pineda; Narimon Honarpour; Anthony C Keech; Peter S Sever; Terje R Pedersen Journal: Lancet Diabetes Endocrinol Date: 2017-09-15 Impact factor: 32.069
Authors: Marc S Sabatine; Robert P Giugliano; Stephen D Wiviott; Frederick J Raal; Dirk J Blom; Jennifer Robinson; Christie M Ballantyne; Ransi Somaratne; Jason Legg; Scott M Wasserman; Robert Scott; Michael J Koren; Evan A Stein Journal: N Engl J Med Date: 2015-03-15 Impact factor: 91.245
Authors: Jennifer G Robinson; Michel Farnier; Michel Krempf; Jean Bergeron; Gérald Luc; Maurizio Averna; Erik S Stroes; Gisle Langslet; Frederick J Raal; Mahfouz El Shahawy; Michael J Koren; Norman E Lepor; Christelle Lorenzato; Robert Pordy; Umesh Chaudhari; John J P Kastelein Journal: N Engl J Med Date: 2015-03-15 Impact factor: 91.245
Authors: Robert A Scott; Nicholas J Wareham; Luca A Lotta; Stephen J Sharp; Stephen Burgess; John R B Perry; Isobel D Stewart; Sara M Willems; Jian'an Luan; Eva Ardanaz; Larraitz Arriola; Beverley Balkau; Heiner Boeing; Panos Deloukas; Nita G Forouhi; Paul W Franks; Sara Grioni; Rudolf Kaaks; Timothy J Key; Carmen Navarro; Peter M Nilsson; Kim Overvad; Domenico Palli; Salvatore Panico; Jose-Ramón Quirós; Elio Riboli; Olov Rolandsson; Carlotta Sacerdote; Elena C Salamanca; Nadia Slimani; Annemieke Mw Spijkerman; Anne Tjonneland; Rosario Tumino; Daphne L van der A; Yvonne T van der Schouw; Mark I McCarthy; Inês Barroso; Stephen O'Rahilly; David B Savage; Naveed Sattar; Claudia Langenberg Journal: JAMA Date: 2016-10-04 Impact factor: 56.272
Authors: Paul F Lebeau; Jae Hyun Byun; Khrystyna Platko; Ali A Al-Hashimi; Šárka Lhoták; Melissa E MacDonald; Aurora Mejia-Benitez; Annik Prat; Suleiman A Igdoura; Bernardo Trigatti; Kenneth N Maclean; Nabil G Seidah; Richard C Austin Journal: JHEP Rep Date: 2019-11-05
Authors: Joseph D Szustakowski; Suganthi Balasubramanian; Erika Kvikstad; Shareef Khalid; Paola G Bronson; Ariella Sasson; Emily Wong; Daren Liu; J Wade Davis; Carolina Haefliger; A Katrina Loomis; Rajesh Mikkilineni; Hyun Ji Noh; Samir Wadhawan; Xiaodong Bai; Alicia Hawes; Olga Krasheninina; Ricardo Ulloa; Alex E Lopez; Erin N Smith; Jeffrey F Waring; Christopher D Whelan; Ellen A Tsai; John D Overton; William J Salerno; Howard Jacob; Sandor Szalma; Heiko Runz; Gregory Hinkle; Paul Nioi; Slavé Petrovski; Melissa R Miller; Aris Baras; Lyndon J Mitnaul; Jeffrey G Reid Journal: Nat Genet Date: 2021-06-28 Impact factor: 38.330